PARP1 and chondrosarcoma: Our study provides the rationale for a further exploration of talazoparib and temozolomide for chondrosarcoma in an orthotopic mouse model, such as the one developed by our group [38], and those studies should assess a combination of low-concentration talazoparib and temozolomide, as well as a combination of temozolomide with recently developed lower-toxicity PARP inhibitor treatment options.